RAYNE ROUCE to Cell- and Tissue-Based Therapy
This is a "connection" page, showing publications RAYNE ROUCE has written about Cell- and Tissue-Based Therapy.
Connection Strength
1.752
-
Cell and gene therapy accessibility. Science. 2024 Aug 02; 385(6708):475.
Score: 0.848
-
Enhancing pediatric access to cell and gene therapies. Nat Med. 2024 Jul; 30(7):1836-1846.
Score: 0.210
-
Targeted cellular therapy for treatment of relapsed or refractory leukemia. Best Pract Res Clin Haematol. 2023 09; 36(3):101481.
Score: 0.195
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.166
-
A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
Score: 0.150
-
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
Score: 0.098
-
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 Aug; 30(8):776-787.
Score: 0.052
-
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
Score: 0.032